

بسم الله الرحمن الرحيم





شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم



جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار





بعض الوثائق الأصلية تالفة






بالرسالة صفحات لم ترد بالأصل



PENTOSIDINE, AN ADVANCED GLYCATION END-PRODUCT, AS A NEW BIOCHEMICAL MARKER IN DIFFERENT CLINICAL DISEASES

Essay

Submitted For Partial Fulfillment of
Master Degree in Clinical Pathology



By,

Hany Morris Danial
M.B., B.C.h.

67065

616.07561

H.M.

Under supervision

Prof. Dr. Nasser Sadek Rezk

Professor of Clinical and Chemical Pathology

Faculty of Medicine

Ain Shams University

Dr. Aziza Ahmed El Sebai

Assistant Prof. of Clinical and Chemical Pathology

Faculty of Medicine

Ain Shams University

Dr. Manal Abdel Baky Mahmoud

Lecturer of Clinical and Chemical Pathology

Faculty of Medicine

Ain Shams University

Faculty of Medicine
Ain Shams University
2000



Acknowledgement

First, I thank "God" for granting me the power to proceed and to accomplish this essay.

I would like to express my endless gratitude and appreciation to Prof. Dr. Nasser Sadek Rezk, Professor of Clinical and Chemical Pathology, Ain Shams University, for giving me the honor of working under his supervision and for providing me with a lot of encouragement and support throughout this essay.

Indeed, words do fail me when I come to express my sincere appreciation to Assistant Prof. Dr. Aziza Ahmed El Sebai, Assistant Professor of Clinical and Chemical Pathology, Ain Shams University, who was always there to solve all my problems by giving valuable remarks throughout this work.

Also, I would like to express my gratitude and thanks to Dr. Manal Abdel Baky Mahmoud, Lecturer of Clinical and Chemical Pathology, Ain Shams University, for her effort to get best out of this work, her encouragement, and honest assistance in every step of this essay.

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

2000

Contents

	Page
List of Abbreviations	i
List of Figures	ii
List of Tables	iii
I-Introduction and aim of the work	1
II-Review of literature	4
1-Pentosidine:	4
A)Historical background.....	4
B)Definition and chemical structure.....	5
i- Forms.....	11
ii- Reference ranges.....	11
iii- Sites.....	12
iv- Degradation.....	12
C) Actions.....	14
D)Effects of age on pentosidine.....	15
2-Methods of assay:	17
A)Specimen.....	17
B)Storage.....	17
C)Analytical methods.....	18
i-HPLC.....	18
ii-ELISA.....	22
3-Clinical applications	26

A)Diabetes Mellitus.....	26
B)Renal failure.....	42
C)Collagen diseases.....	51
D)Kidney and kidney-pancreas transplantation	58
E)Amyloidosis.....	63
F)Effect of drugs on pentosidine.....	64
III- Summary and Conclusion.....	66
IV- References.....	68
V- Arabic summary	

List of Abbreviation

AGEs	Advanced glycation end products
Alb	Albumin
BSA	Bovine serum albumin
CAPD	Continous ambulatory peritoneal dialysis
CML	Carboxy methyl lysine
CMHL	Carboxy methyl hydroxy lysine
CRP	C-reactive protein
DHA	Dehydroascorbic acid
DK	Diabetic kidney transplant
DKP	Diabetic kidney-pancreas
DTPA	Diethylene triamine pentacetic acid
EDTA	Ethylene diamine tetra-acetic acid
ELISA	Enzyme linked immunosorbent assay
HD	Hemodialysis
HFBA	Hepatofluorobutyric acid
HPLC	High performance liquid chromatography
IDDM	Insulin dependent diabetes mellitus
Na BH ₄	Sodium borohydride
NDK	Non diabetic kidney transplant
NIDDM	Non insulin dependent diabetes mellitus
OA	Osteoarthritis
Pen.	Pentosidine
Pyr	Pyridinoline
RA	Rheumatoid arthritis
SLE	Systemic lupus erythematosus

1. The first part of the document is a list of names and addresses of the members of the committee.

List of Figures

Figure 1	Structure of pentosidine	6
Figure 2	Mechanism of pentosidine formation	8
Figure 3	HPLC system with a column-switching valve	19
Figure 4	Reactions of glycation and browning	30
Figure 5	Relation between duration of diabetes and pentosidine content in human aorta	36
Figure 6	Correlation between creatinine clearance and plasma level of pentosidine	45
Figure 7	Relation between plasma levels of neopetrin and pentosidine in uremic patients	47

